Redeye provides its first take on Hansa Biopharma's Q1 report. Revenues were SEK35m in the quarter, a decline Q/Q and Y/Y and lower than our forecast. Although this was likely expected, we expect a negative share price reaction when the market opens.
LÄS MER
